{"entity":{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","aka":[],"tldr":"Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma.","summary":"Michael Dickinson was principal investigator and first author of the pivotal phase 2 trial of glofitamab, the CD20xCD3 bispecific antibody that produces durable complete remissions in about 40% of patients with relapsed or refractory large B-cell lymphoma after two or more lines, including after CAR-T, leading to its approval. He leads bispecific and CAR-T trials at Peter Mac and the Australasian Leukaemia and Lymphoma Group aggressive lymphoma programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dickinson%20MJ%5BAuthor%5D%20glofitamab"}],"tags":["lymphoma","bispecific","australia"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["cd20","cd3"],"drugs":["glofitamab"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["starglo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Lead, Aggressive Lymphoma Program, Peter MacCallum Cancer Centre and Royal Melbourne Hospital","institutionId":"peter-mac","specialisms":["Aggressive lymphoma","Bispecific antibodies","CAR T-cell therapy","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dickinson%20MJ%5BAuthor%5D%20glofitamab"}],"papers":[{"title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2206913"},{"title":"Glofitamab plus gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma (STARGLO)","journal":"Lancet","year":2024}],"orcid":"0000-0002-1492-5966"},"route":"/people/michael-dickinson/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"trial":[{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/"}],"paper":[{"id":"paper-belinda-tisagenlecleucel-second-line-nejm-2022","kind":"paper","name":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","route":"/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}